1492 related articles for article (PubMed ID: 27122660)
1. Nonalcoholic fatty liver disease as a multi-systemic disease.
Fotbolcu H; Zorlu E
World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease - A multisystem disease?
Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
4. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
Vanni E; Marengo A; Mezzabotta L; Bugianesi E
Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
6. [Non-alcoholic fatty liver disease (NAFLD)].
Rau M; Weiss J; Geier A
Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
[TBL] [Abstract][Full Text] [Related]
7. Extrahepatic Complications of Nonalcoholic Fatty Liver Disease.
Chacko KR; Reinus J
Clin Liver Dis; 2016 May; 20(2):387-401. PubMed ID: 27063276
[TBL] [Abstract][Full Text] [Related]
8. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications.
Miele L; Targher G
Expert Rev Gastroenterol Hepatol; 2015; 9(10):1243-5. PubMed ID: 26224399
[TBL] [Abstract][Full Text] [Related]
9. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?
Ahmed MH; Ali A
Scand J Gastroenterol; 2014 May; 49(5):521-7. PubMed ID: 24646400
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease: Evolving paradigms.
Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
[TBL] [Abstract][Full Text] [Related]
13. An update on nonalcoholic fatty liver disease.
Provencher DM
JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease and non-liver comorbidities.
Manikat R; Nguyen MH
Clin Mol Hepatol; 2023 Feb; 29(Suppl):s86-s102. PubMed ID: 36603574
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection.
Krahn T; Martel M; Sapir-Pichhadze R; Kronfli N; Falutz J; Guaraldi G; Lebouche B; Klein MB; Wong P; Deschenes M; Ghali P; Sebastiani G
J Infect Dis; 2020 Aug; 222(5):787-797. PubMed ID: 32249283
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
Alkassabany YM; Farghaly AG; El-Ghitany EM
Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
Fargion S; Porzio M; Fracanzani AL
World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
[TBL] [Abstract][Full Text] [Related]
20. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis.
Kanwar P; Kowdley KV
Clin Liver Dis; 2016 May; 20(2):225-43. PubMed ID: 27063266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
